ArticleFrontiers in immunology2021
NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 72 citations in OpenAlex.
- Simulation-guided design of peptide-metal coordination interfaces for next-generation metallo-immunotherapy.Nano convergence · 2026Review
- AI-driven computational methods and benchmarking for T-cell antigen identification.Briefings in bioinformatics · 2026Review
- Dysregulated immune microenvironment in metastatic colorectal cancer.Medical oncology (Northwood, London, England) · 2026Article
- CNNeoPP: a large language model-enhanced deep learning pipeline for personalized neoantigen prediction and liquid biopsy applications.Frontiers in immunology · 2026Article
- The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.Frontiers in oncology · 2026Review
- Computational neoantigen prediction for cancer immunotherapy.Genes and immunity · 2025Review
- A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class I-restricted neoantigens.Briefings in bioinformatics · 2025Article
- NovumRNA: Accurate prediction of non-canonical tumor antigens from RNA sequencing data.iScience · 2025Article
- Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.Genomics, proteomics & bioinformatics · 2025Review
- Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy.Biomarker research · 2025Review
- Article
- OmniNeo: a multi-omics pipeline incorporating proteomics and AI selection for neoantigen optimization in tumor immunotherapy.Frontiers in immunology · 2025Article
- NeoTImmuML: a machine learning-based prediction model for human tumor neoantigen immunogenicity.Frontiers in immunology · 2025Article
- Article
- ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis.Nature communications · 2024Article
- IMGT/RobustpMHC: robust training for class-I MHC peptide binding prediction.Briefings in bioinformatics · 2024Article
- Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types.Nature biotechnology · 2024Article
- Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.International journal of molecular sciences · 2024Review
- AutoEpiCollect, a Novel Machine Learning-Based GUI Software for Vaccine Design: Application to Pan-Cancer Vaccine Design Targeting PIK3CA Neoantigens.Bioengineering (Basel, Switzerland) · 2024Article
- A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes.NAR cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell recognition of somatic mutation-derived cancer neoepitopes can lead to tumor regression. Due to the difficulty to identify effective neoepitopes, constructing a database for sharing experimentally validated cancer neoantigens will be beneficial to precise cancer immunotherapy. Meanwhile, the routine neoepitope prediction
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.